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Abstract
Background: Acceptance and Commitment Therapy (ACT) has been successfully established in hundreds of
efficacy trials. It is less understood, however, how ACT works in real-world settings. Furthermore, little is known
about how contextual variables such as treatment setting (inpatient vs. outpatient), social network and environment
of the patient impact outcome.
Methods: This paper describes the methods of the Choose Change study that compares transdiagnostic inpatients
(n = 85) and outpatients (n = 85) with varying degrees of treatment experience and treatment success (i.e., no
previous treatment vs. previous remission vs. treatment-resistant). Patients received ACT during an intensive
treatment phase lasting approximately twelve treatment sessions, and were accompanied up to twelve months
following intensive treatment. Main outcomes include symptoms, functioning, and well-being. Multiple levels of
data are investigated, including treatment context, weekly assessments, a behavioral approach test, multiple follow-
up phases, and ambulatory assessment using Event Sampling Methodology, to examine patients’ daily context.
Discussion: We aim to investigate antecedents, consequences, and inherent processes that contribute to the
maintenance or fluctuations of psychological disorders and the efficacy of ACT treatment. Furthermore, this study
intends to increase understanding of how accurately participants can report on their own experiences, in order to
expand our knowledge of how to probe for such information in the future. The results of Choose Change will
provide basic clinical theory and clinical care with important and meaningful insights into the effectiveness of ACT,
trans diagnostically, in in- and outpatients, and in a naturalistic setting.
Trial registration: This study was retrospectively registered in the ISRCTN Registry (registration number
ISRCTN11209732) on May 20th 2016.
Keywords: Acceptance and commitment therapy (ACT), Effectiveness, Inpatients, Outpatients, Transdiagnostic,
Psychological flexibility, Implementation
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Background
Acceptance and commitment therapy
Acceptance and commitment therapy (ACT) has been
shown to be efficacious in numerous disorders, such as
anxiety and depression (e.g., [1]), psychosis (e.g., [2]), pho-
bias (e.g., [3]), alcohol use, anger, and stress (e.g., [4]), obes-
ity (e.g., [5]), burnout [6], and treatment-resistant patients
[7]. ACT aims to increase psychological flexibility, which
has been shown to increase mental health in over 250 ran-
domized controlled clinical trials across numerous disor-
ders [8]. Psychological flexibility is defined as someone’s
ability to “recognize and adapt to various situational de-
mands; shift mindsets or behavioral repertoires when these
strategies compromise personal or social functioning;
maintain balance among important life domains; and be
aware, open, and committed to behaviors that are congru-
ent with deeply held values” ( [9], p865). Preliminary evi-
dence suggests that symptomatology itself does not explain
whether someone is functioning with a high level of
well-being [10] and there is also evidence that psychologic-
ally flexible responses to changing demands promote ad-
vantageous outcomes [11]. This speaks to a tendency in
basic behavioral science and research away from
disorder-specific characteristics and processes, towards
processes that potentially underlie multiple disorders and
clinical states [12]. However, despite ACT being a trans-
diagnostic approach [13], there are few transdiagnostic (i.e.,
applicable across diagnostic categories as opposed to a sin-
gle disorder) effectiveness studies (e.g., [14, 15]). Further,
despite the studies investigating ACT’s efficacy, important
questions remain, for example, specification of the mecha-
nisms of action, stability of change, and how well it can be
implemented into routine clinical practice [16]. However,
in clinical trials, the mechanisms of change are far from
clear, and integrated assessment is as necessary as it is diffi-
cult to implement. Overall, this study investigates three key
aspects: The effectiveness of ACT, long- term follow-up,
and the social context and social processes.
Effectiveness of acceptance and commitment therapy
There is also a need to improve our understanding of the
effectiveness of ACT, stressing real-world settings across
broad populations with the goal of maximizing external
validity [17]. While the importance of Randomized Con-
trolled Trials (RCTs) and efficacy studies is evident, such
tightly controlled and randomized studies might neglect
crucial factors of what is done in the field [18], and thus
less likely reflect conditions under which interventions are
used in common clinical practice [19]. Non-randomized
trials are often more externally valid than RCTs because
they include all patients, are conducted under conditions
that more closely match how practitioners will ultimately
implement the treatment, and include more context vari-
ables (such as patient-practitioner relationship, [20]).
Objective and subjective ratings need to be assessed, for
instance through paradigms assessing psychological flexi-
bility during a psychological challenge (i.e. a behavioral ap-
proach test).
Long-term follow-up
Relatively little is known about the processes that unfold
following treatment, for instance, whether or how patients
integrate newly learned skills into their daily environment,
and how these factors interrelate with well-being of both
the patients and their social networks. Processes following
treatment have traditionally been examined with a single
assessment concentrating on symptomatology, which is
why researchers have been encouraged to include longer
follow up periods in clinical studies [21]. The period follow-
ing treatment is risky if patients stop applying what was
learned during therapy or are confronted with challenges
[21, 22]. This is especially true for treatment-resistant pa-
tients (i.e., patients who do not respond to standard, first
line treatments), for whom viable treatment options are
lacking and even less is known about than about first-line
treatments [7]. To determine if ACT can meaningfully im-
pact treatment-resistant patients in routine practice, a study
population including treatment-resistant patients across
diagnoses treated in real-world settings is essential. Inclu-
sion of non-treatment-resistant patients, however, is im-
portant as well to inform about treatment-resistant ones.
Social context and social processes
Factors outside therapy itself, including social processes,
are believed to account for approximately 33% of im-
provement in patients undergoing psychotherapy [23].
Despite the importance of social context, it remains
poorly understood how the influence of social surround-
ings (e.g., supportive vs. counterproductive) longitudin-
ally affects the patient’s well-being and prosociality (i.e.,
cooperating with others, acting for the well-being of
others, and sacrificing for others, [24, 25]) and how this
in turn affects the patient’s social context. Tracking the
transition into the real world after treatment is therefore
crucial. The challenges and risks of relapse during this
period may be more extreme for inpatients than outpa-
tients, as their change of environment (i.e., leaving the
hospital) is more extreme; however, this has not been
tested directly. Furthermore, it is completely unknown
how the influence of these social variables is moderated
by psychological flexibility. Patients treated in an in-
patient setting with more negative relationships in their
extended social network have been found to relapse
more frequently [26]. This suggests that both close and
extended social ties are relevant for outcomes, and that
these impact multiple forms of treatments. More re-
search is sorely needed to better understand the mecha-
nisms that influence a patient and their social context,
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particularly in disorders beyond depression and in
non-cross-sectional studies that allow the temporal
order of effects to be disentangled [27, 28]. The few
existing longitudinal studies have identified a bidirectional
link between couple distress and depression [27, 28] and to
a lesser extent between couple distress and substance abuse
[29, 30] and between couple distress and anxiety [30]. Rela-
tively little emphasis has been placed on outcomes of func-
tioning, well-being, or prosocial behaviors – neither in the
treated patient nor the immediate and extended social net-
work. As such, little is known about the interaction between
treatment, social context, and these broader outcomes.
Building on these insights, the necessity to understand
patients’ behavior in their natural environment becomes
clear [31]. Daily life happens in specific environmental
contexts, and there is a need to understand these contexts.
Implementing Event Sampling Methodology (ESM) allows
the examination of patients’ daily life and its stressors, in-
cluding the assessment of moods, thoughts, symptoms or
behaviors, which change over time [31, 32]. Thus, eco-
logically valid data can be collected in a real-time fashion
while capturing dynamic changes of variables [33].
Study aims
The major aim of Choose Change is to longitudinally
examine the mechanisms of action involved in an ACT
treatment for transdiagnostic patients with varying de-
grees of treatment experience and treatment success in a
controlled effectiveness trial in order to maximize exter-
nal validity [17]. More specifically, it will be tested how
psychological flexibility training (i.e., ACT) influences
various outcomes across time and document how the
intervention is implemented in patients’ everyday lives
following the treatment. Simultaneously, state-of-the-art
methods are used to ascertain processes of change and
maintain internal validity. Increased use of technological
innovations, such as mobile phones, will provide us with
more information about the common and specific effects
of psychological treatments [34]. This is the first project
to test the effects of the social context of treatment set-
tings (in- vs. out-patient) and the transition out of inten-
sive treatment to well-being, functionality, and recidivism
following a modern transdiagnostic behavioral treatment
promoting psychological flexibility.
Main research areas
We will investigate the immediate and long-term outcomes
of treating treatment-resistant patients with psychological
flexibility training (i.e., ACT) in two treatment-related social
contexts (i.e., inpatient and outpatient), and the influence of
other, naturally occurring social contexts (e.g., self-chosen
contexts such as home, work etc.) on various treatment
outcomes. These research areas include broad outcomes
(i.e., indices of well-being, functioning, social interactions,
and prosocial behavior) in addition to symptoms and recid-
ivism, thus going beyond a symptom-based focus.
On the basis of these main research questions, we de-
rived the following main hypotheses: First, we expect the
ACT intervention to lead to significant and clinically
relevant changes during treatment that remain stable or
increase at 12-month follow-up. Second, patients treated
in the inpatient setting will experience more intense and
frequent social stressors in the follow-up period than
those treated in the outpatient setting, which will have a
negative impact on outcomes. Third, psychological flexi-
bility will moderate the negative impact of social stress
on outcomes over time, so that it is buffered in patients
with high levels of psychological flexibility.
Method
Design
This is a controlled effectiveness clinical trial. The study
contains multiple seven-day-ESM phases, four intensive
follow-up assessments at 1, 4, 9, and 12months follow-
ing intensive treatment, weekly measures during treat-
ment, and a behavioral approach test, while considering
the effects of the social context of treatment settings (in-
vs. outpatient), and following a modern transdiagnostic
behavioral treatment promoting psychological flexibility.
Figure 1 illustrates an overview of the study design.
Sample size
Power analyses were conducted with alpha = 0.05,
power = 0.8, two-sided test, for within group and be-
tween group hypotheses. We assumed a correlation be-
tween time points = 0.5 and based on previous work
(Gloster et al., 2015), a small to medium effect size was
assumed. Required sample sizes were 75 individuals for
within group research and 150 patients (75 per group)
for between-group hypotheses. Taking missing values
into account (ca. 10% dropout), the required sample size
in order to have sufficient power for all three hypotheses
was thus approximately 170 individuals. We therefore
aim to recruit n = 85 patients per treatment modality.
Participant recruitment and selection criteria
Participants are recruited from two specialized clinics
practicing ACT (inpatient and outpatient) from ongoing
referral and intake procedures. Since ACT is a transdiag-
nostic therapy which is efficacious for many disorders,
and in order to increase generalizability within this effect-
iveness trial, selection criteria are purposefully kept to a
minimum. Inclusion criteria are: Minimum 18 years of
age, ability to speak German sufficiently, present for ther-
apy and able to attend sessions, previous treatment (i.e., ≥
20 sessions of empirically supported psychotherapy and/
or minimum dosage and length of an approved drug as
recommended by international guidelines), and sign a
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consent statement will be included the study. In addition,
for patients in the out-patient setting, patients will also be
included with < 20 sessions therapy experience to enable
full modelling of patients from those without treatment
experience, to those with treatment experience in the out-
patient setting, to those with treatment experience in the
inpatient setting. Exclusion criteria include acute suicidal
intent, acute substance dependency, (where the primary
treatment goal is detoxification), active mania, previous
experience with ACT, and inability to read or complete as-
sessments. Otherwise all diagnoses are included (i.e.
Affective Disorders, Anxiety Disorders, Somatoform Dis-
orders, Mood Disorders, Anxiety-stress related Disorders,
Somatic Disorders, Obsessive-Compulsive Disorder, Im-
pulse Control Disorders, Gambling Disorders, and Per-
sonality Disorders). When participants enter the clinic,
medication is optimized when necessary, as determined
by the attending physician in consideration of patient pref-
erence. Medication is then held constant throughout the
intensive treatment phase.
Outcome assessments
Assessments in questionnaire and interview format will
occur at six primary time points to capture changes that
the patients choose in the following domains: Therapy
expectancy, psychological flexibility, social interactions,
therapy consistent skills, well-being, emotion regulation,
symptomatology, stress, and prosocial behavior. ESM
will target the same domains. Table 1 shows a brief de-
scription of the assessments. Assessments are done by
psychology graduates and doctoral students. Assessors
are trained to competency and supervised regularly. All
utilized assessments were chosen based on covering the
respective domain and adequate quality criteria.
Primary outcome measures will target symptoms and
general functioning. These are assessed using question-
naires completed by the patients using the Brief Symp-
tom Checklist (BSCL; to assess symptoms), the World
Health Organization Disability Assessment Schedule – 2
(WHODAS 2; to assess functioning), and the Mental
Health Continuum – Short Form (MHC-SF; to assess
well-being). Primary outcomes are measured at baseline,
post, and 12months following treatment. The MHC-SF
is measured at all time points.
Secondary outcomes are included to assess additional do-
mains, such as treatment context, social context, spreading
of effects, follow-up, daily context, and behavioral measures
(see Table 2 and Table 3). In addition, an experimental para-
digm will be used to measure how psychological flexibility
impacts patients’ behavioral response to experimentally in-
duced discomfort (i.e., radiant heat pain). This radiant heat
pain paradigm is commonly used in research [35, 36] and
Fig. 1 Illustration of the study design. Note. Smartphone, Heat Induction Test, Assessment is administered at Baseline, Post, and 12-month follow-
up. Process assessment is assessed weekly during the intensive treatment phase by the patient, therapist, and nurse (in the case of the inpatient
setting). Assessment through questionnaires and interview are administered at 1-, 4-, and 9-month follow up. BL: Baseline; P: Patient; T: Therapist;
N: Nurse (only for the inpatient setting). FU-1, FU-4, FU-9, FU-12: Assessments at 1-, 4-, 9-, and 12-month follow up
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Table 2 Overview of domains, constructs, assessments, and respective time points at which each assessment is administered
Choose Change: Assessment Overview
Domain Construct Instrument/Paradigm Assessment Time
BL Post FU-
1
FU-
4
FU-
9
FU-
12
Therapy Expectancy Expectancy Credibility and Expectancy Questionnaire (CEQ) x
Psychological
Flexibility
Psychological Flexibility/ Emotional
Avoidance
Acceptance and Action Questionnaire – II (AAQ-II) x x x
Process of Psychological Flexibility PsyFlex (PF) x x x x x x
Behavioral Test/Experiment Behavioral Avoidance Test (BAT): Heat Induction
Test
x x x
Social interactions Overall Social Support Oslo Social Support Scale (OSS-3) x x x
Social Interaction Social Interaction Scale (SIS) xi xi x x x xi
Relationship Satisfaction Relationship Assessment Scale (RAS) xi xi x xi
Social Network Quality Social Network Quality and Action Scale (SNQAS) xi xi x x x xi
ACT-Skills Cognitive Fusion Cognitive Fusion Questionnaire (CFQ) x x x
Mindfulness Five Facet Mindfulness Questionnaire - short
version (FFMQ-FS)
x x x
Values Valued Living Questionnaire (VLQ) x x x
Well-being General Functioning WHO Disability Assessment Schedule 2.0 (WHODAS
2)
xp x x
Flourishing Mental Health/ well-
being
Mental Health Continuum – Short Form (MHC-SF) xip xi xi xi xi xi
Meaning of Life Meaning in Life Questionnaire (MLQ) x x x
Emotion Regulation Problematic Emotion Regulation Difficulties in Emotion Regulation Scale (DERS) x x x
Emotion Regulation Affective Style Questionnaire (ASQ) x x x
Diagnosis/
Symptomatology
DSM Diagnostic Information Structured Clinical Interview for DSM-IV (SCID-I/
Screener)
x
Depression Beck Depression Inventory – Fast Screen (BDI-FS) x x x x x x
Problems and Discomfort Brief Symptom Checklist (BSCL) xp x x
Worry (GAD) Penn State Worry Questionnaire (PSWQ) (x) (x) (x) (x)
Anxiety/Fear Fear Questionnaire (FQ) (x) (x) (x) (x)
Obsessions and Compulsions (OCD) The Obsessive-Compulsive Inventory, short Version
(OCI-R)
(x) (x) (x) (x)
Social Fear Social Interaction Anxiety Scale (SIAS) (x) (x) (x) (x)
Stress Perceived stress Perceived Stress Scale (PSS) x x x
Daily stress Daily Stress Scale (DSS) xi xi x x x xi
Prosocial Behavior Prosocial Behaviors Developmental Assets Profile – Prosocial Subscale
(DAP-PS)
x x x
Prosociality Questionnaire (EVOS) x x x
Cooperation Cooperation Scale (COOP) x x x
The Self-Report Altruism Scale (SRAS) x x x
Therapy Consistent
Skills
Transfer of Skills to Daily Life Vignettes x x x x
Note. BL = Baseline; FU-1, FU-4, FU-9, FU-12 = Assessments at 1-, 4-, 9-, and 12-month follow up; ESM = Event Sampling Methodology (smartphone); i = to be
completed by close person in addition to patient; () = to be filled out only by patients who have that specific symptomatology (SCID); p = primary outcome
measures
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will be administered at baseline, post, and 12months after
treatment.
In order to test whether treatment context has an im-
pact on patients’ well-being and functioning (i.e. flour-
ishing) [37], ACT will be administered for both in- and
outpatients. For inpatients, a multidisciplinary team is
involved, consisting of psychotherapists providing indi-
vidual and group therapy and the nursing and support
staff providing ACT specialized sessions. For outpatients,
psychotherapists provide individual ACT sessions. All
psychotherapists are certified for this study through at-
tendance of several ACT trainings and provision of a
certification role play video rated by a certified ACT
trainer. Therapists will make choices based on ACT
skills and procedures, which will all be documented fol-
lowing each session. This allows for the documentation
of ACT’s clearly defined skills, while enabling a flexible
and situationally sensitive application.
Baseline: diagnostics, assessment
During the first week of therapy participants complete
informed consent procedures before data collection. All
participants complete the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID) [38] to determine
diagnostic status. Diagnoses are rated on the Anxiety
Disorders Interview Schedule (ADIS) severity rating
scale [39]. The diagnosis with the highest severity score
determines the primary diagnosis. Following the SCID,
participants complete diagnostic-specific and transdiag-
nostic questionnaires (see Table 2).
Post: assessment
At completion of the intensive therapy phase post as-
sessment is done (i.e. diagnostic-specific and
transdiagnostic questionnaires, ESM, and the heat induc-
tion test). Except for the SCID and the Credibility and
Expectancy Questionnaire (CEQ) procedures and items
will be the same as in baseline (see Table 2 and Table 3).
Follow-up: 1, 4, 9, and 12 months after treatment
In order to assess what was learned during therapy and
how psychological flexibility, well-being, and symptoms
are associated with each other, patients stay in contact
with the research team after completing the intensive in-
patient or outpatient treatment phase. Over the following
year, four follow-up appointments are conducted at 1, 4,
9, and 12 months after completion of the intensive ther-
apy phase. Follow-up appointments include an online
questionnaire and an interview. For the included ques-
tionnaires see Table 2.
Assessments measuring mechanisms of action across
levels of analysis
Behavioral approach test
A heat induction test (using the TSA-II, [40]) was used
in order to test how participants respond to an uncom-
fortable and ambiguous stimulus not subject to the same
demand characteristics as questionnaires. During this
test, temperature increases until the patient stops the in-
crease with a click of the mouse. This temperature is
then held constant to test tolerance. This test is adminis-
tered at Baseline and Post (to determine whether the tol-
erance changes during treatment) and at Follow-Up 12
(to determine whether the tolerance changes after treat-
ment). Before and after participants will complete a
pain-related questionnaire.
Weekly psychological flexibility process measure (between
baseline and post)
In order to examine whether patients with higher levels
of psychological flexibility will profit faster from treat-
ment, weekly psychological flexibility progression will be
measured during the intensive treatment phase (between
Baseline and Post). For this, the PsyFlex [41, 42] will be
used across different information sources. The PsyFlex is
a self-developed instrument which aims at measuring
state psychological flexibility through capturing all six
skills of the ACT Hexaflex [43]. The PsyFlex is filled out
by the patients, their therapists, and – in the inpatient
setting – their nurse, which results in an evaluation of
one person from up to three different perspectives.
Ambulatory monitoring (ESM at baseline, post, and 12
months after treatment)
In order to examine how psychological flexibility and
other treatment parameters were applied to stressors
in real-time in the participants’ natural environment,
Table 3 Overview of domains and respective time points at
which each EMA assessment is administered
Choose Change: Assessment Overview
Domains assessed Assessment Time for ESM
BL Post FU-12
Therapy Expectancy
Psychological Flexibility x x x
Social interactions x x x
ACT-Skills x x x
Well-being x x x
Emotion Regulation x x x
Diagnosis/ Symptomatology x x x
Stress x x x
Prosocial Behavior x x x
Therapy Consistent Skills
Note. BL Baseline, ESM Event Sampling Methodology (smartphone), FU-12
Assessments at 12-month follow up
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how social group interactions affected the individual,
and how these aspects changed over time, patients re-
ceive a smartphone from the research team and in-
structions on its usage (i.e. operation of the
smartphone, recognition of the signaling tone, answer
example questions). Data will be collected at Baseline,
Post, and Follow-Up 12. At each time point, patients
will carry the smartphone for one week, using a
signal-contingent ESM approximately every three
hours (e.g., 8 am, 11 am, 2 pm, 5 pm, 8 pm, and 11
pm). Items stem from previous ESM studies [44–47]
and are based on a functional analysis of social inter-
actions [48] due to their individual nature. In addition
to the data assessed via questionnaires, GPS data (e.g.
time-stamped data regarding location, speed of travel
if travelling, and time spent at different locations) of
the patients will be collected during the respective
ESM week. For assessed domains within the ambula-
tory assessement, see Table 3.
Close person (baseline, post, and 12 months after
treatment)
In order to investigate the impact of the social context,
patients are asked to give the research team permission
to contact a person of their choice, who is close to them.
This close person is then contacted by the research
team. After obtaining informed consent from this close
person, an online questionnaire is completed at Baseline,
Post, and at Follow-Up 12 by the close person, providing
information about their relationship and well-being. For
the included questionnaires see Table 2.
Therapy integrity
Therapy will consist of an intensive treatment phase
lasting approximately twelve treatment sessions. Thera-
pists will be certified for this study. Therapy sessions will
be recorded and of those, two will be randomly selected
and rated by external and independent ACT experts to
assess treatment integrity. Therapy integrity will be fur-
ther promoted via regular targeted supervision sessions
by ACT experts.
Analysis plan
For all analyses we will use multilevel models with time
as level 1 and person as level 2 variables. These models
are able to deal with the interdependence of observa-
tions across time within the same subject. Hypothesis 1
refers to a multilevel model with time as within-subjects
variable and no between-subjects variable. Hypothesis 2
is based on hypothesis 1 but will contain in addition one
between-subjects factor (group, 2 levels), plus the inter-
action between time and group, which is our primary
focus. Hypothesis 3 refers to a multilevel model with so-
cial stress as predictor and psychological flexibility as
mediator. Again, we will be interested in the interaction
between these two characteristics, which are both
time-varying within subjects.
Discussion
The aim of this study is to longitudinally examine the
mechanisms of action involved in an Acceptance and
Commitment Therapy (ACT) treatment for transdiagnos-
tic patients with varying degrees of treatment experience
in a controlled effectiveness trial. This study captures the
treatment effectiveness of ACT, in addition to assessing
psychological flexibility and patients’ social contexts in
multiple ways over multiple time points, up to 12months
after intensive in- or outpatient treatment. A large sample
consisting of patients with various diagnoses is recruited,
in accordance with ACT being a transdiagnostic behav-
ioral approach. Novel methods of data collection (Event
Sampling Methodology, ESM) are combined with trad-
itionally used ones such as questionnaires (implemented
at many time points in many ways) and a behavioral ap-
proach test (Heat Induction Test). By capturing treatment
effectiveness (including follow-up to 12months), symp-
toms, emotions, social interactions, stressors, psycho-
logical flexibility, spreading of effects to the patient’s social
network, well-being, and health-behaviors as well as be-
havioral variables, and fluctuations of all these, this study
will add to the understanding of antecedents, conse-
quences, and inherent processes that contribute to the re-
covery of psychological disorders and maintenance of
gains as well as fluctuations in well-being, functioning and
reduced symptomatology. Furthermore, these data allow
for a better understanding how time affects the accuracy
of participants’ reporting of their own experiences, thereby
contributing to a better understanding of how to better
probe for such information in the future [49]. Therefore,
these data are relevant for both basic clinical theory and
clinical care.
The implementation of ESM enables us to capture ex-
periences in participants’ natural environment. ESM is
also today’s gold standard and allows us to collect infor-
mation closer to real life than data collection solely with
questionnaires. Since participants’ retrospective recalls
are limited to three hours during the ESM week, the
participants will have more accurate memories regarding
that time window than larger time windows (days,
weeks, months, or even years) often enquired about in
questionnaires. Combining ESM, behavioral tests, weekly
process measures filled out by three sources (patient,
therapist, and nurse [in the in-patient setting]), question-
naires, and also information about the participants’ so-
cial networks in a large group of in- or outpatients with
various diagnoses across different severity levels results
in a unique and rich data set.
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These data further the understanding of symptoms,
general functioning, and well-being by testing across dif-
ferent domains, namely therapy expectancy, psycho-
logical flexibility, social interactions, therapy consistent
skills, well-being, emotion regulation, symptomatology,
stress, and prosocial behavior. They will also provide in-
formation about how ACT differentially affects a range
of psychological, behavioral, cognitive, and affective out-
comes. Different components can be identified and re-
lated to symptomatology, maintenance of therapeutic
gains, and relapse.
Finally, Choose Change will generate hypotheses that
will lead to a number of publications that will focus on
how ACT transfers to treatment-resistant patients treated
in in- and outpatient treatment settings. Moreover, the
mechanisms underlying treatment success and failure re-
main largely unknown and findings from Choose Change
are expected to significantly contribute to our understand-
ing in this area. The results of Choose Change will provide
science with important and meaningful insights into the
effectiveness of ACT, trans diagnostically, in in- and out-
patients, and in a naturalistic setting.
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